Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.

Hikmat PermanaNanny Natalia Mulyani SoetedjoTheo Audi YantoMarshell TendeanTimotius Ivan HariyantoKetut Suastika

Published in: Expert review of endocrinology & metabolism (2023)

Our study suggests that imeglimin 1000 mg twice daily may offer the most optimum therapeutic effects for glycemic control without compromising its safety profiles.

Keyphrases

glycemic control
systematic review
type diabetes
blood glucose
physical activity
weight loss
insulin resistance
clinical trial
metabolic syndrome
double blind